How Safety Leaders Are Redefining Drug and Alcohol Compliance

Australian workplace drug and alcohol compliance is more complex than it has ever been. Medicinal cannabis prescriptions have grown at a pace that most workplace policies did not anticipate. State and territory WHS legislation continues to evolve, placing sharper duty-of-care obligations on employers in safety-critical industries. At the same time, the technology available to support testing programs from oral fluid screening devices to cloud-based result management platforms, has advanced well beyond the frameworks many organisations still rely on.

WHS Show Melbourne 2026, held at the Melbourne Convention and Exhibition Centre on 20 and 21 May, brought together safety leaders, WHS professionals, HR managers and industry practitioners across two days of sessions, product demonstrations and peer conversations. For those responsible for drug and alcohol compliance, five shifts in particular deserve attention because each one is already reshaping what a defensible, effective program looks like in 2026.

Oral Fluid Testing Is Becoming the Standard for Real-Time Safety Decisions

Oral fluid testing has become the method of choice for safety-critical industries that need to assess recent substance use rather than historical exposure. Unlike urine testing, which can detect drug metabolites days or weeks after consumption, saliva testing identifies substances within a narrower and more operationally relevant window, typically reflecting use within the past 24 to 48 hours. For post-incident testing, reasonable-suspicion screening and pre-shift checks in high-risk environments, this distinction matters considerably.

AS/NZS 4760:2019 governs oral fluid testing procedures in Australian workplaces, setting out requirements for collection, screening and confirmation processes. Employers in mining, construction, transport and energy who have not yet reviewed their testing method against this standard are operating with a compliance gap that regulators and courts are increasingly unlikely to overlook. Urine testing under AS/NZS 4308:2008 remains appropriate for specific use cases, particularly return-to-work monitoring and rehabilitation programs, where a longer detection window supports ongoing oversight but it is no longer sufficient as the sole method in most high-risk operating environments.

The practical case for oral fluid testing also includes procedural advantages. Collection is non-invasive, requires no same-sex collector and presents fewer chain-of-custody complications than urine collection in field settings. For multi-site employers managing testing across remote locations, these factors reduce both logistical friction and the risk of a procedural challenge to a test result.

The following comparison summarises where each method is most appropriately applied:

Andatech's saliva drug test kits calibrated to AS/NZS 4760:2019, including the DrugSense DSO8 Plus V3 and the DrugSense OraScan Saliva and Surface Drug Test Cassette V5, are designed for the field conditions that safety-critical industries operate in, where speed, chain-of-custody integrity and standard compliance all need to be satisfied at once.

Digital Result Management Is Closing the Gap Between Testing and Compliance Records

Many organisations test regularly but manage their results poorly. Paper-based logs, disconnected spreadsheets and inconsistent record-keeping across sites create a compliance gap that only becomes visible when an incident triggers a WHS investigation or a Fair Work proceeding. At that point, the absence of an auditable, complete testing record can undermine an otherwise defensible program.

Cloud-based result management platforms address this gap by centralising result capture, supporting chain-of-custody documentation and generating reporting dashboards that give safety leaders a real-time picture of testing activity across their operations. For multi-site employers in mining, construction and transport, the operational value is significant: a testing event conducted on a remote WA site can feed into the same compliance record as one conducted at a metropolitan depot, with the same documentation standard applied throughout.

Andalink, Andatech's cloud-based drug and alcohol result management platform, is built to meet this need. It supports centralised compliance data across multiple sites, enables authorised personnel to access and review results without creating security or confidentiality risks, and produces the audit-ready documentation that WHS regulators and legal teams require. Key outcomes that a platform of this kind delivers include:

• Consistent chain-of-custody records across all testing events, regardless of location
• Automated reporting that removes manual data entry and the errors that come with it
• Audit-ready documentation accessible at short notice for regulatory or legal purposes
• Visibility across sites for safety managers overseeing geographically distributed workforces
• A structured record that supports pattern identification and early intervention decisions

For safety leaders evaluating their testing infrastructure after WHS Show Melbourne 2026, the question is not whether digital result management adds value; it is whether the absence of it creates a liability the organisation has not yet quantified.

The Medicinal Cannabis Question Has Moved from Policy to Practice

Medicinal cannabis is no longer an edge case for Australian workplace safety programs. The number of patients dispensed medicinal cannabis in Australia rose from 583 in April 2020 to more than 24,000 by mid-2024, according to evidence presented to the Victorian Parliamentary Inquiry into Workplace Drug Testing. That growth trajectory means employers across every safety-critical industry are now statistically likely to have workers who hold a valid prescription and that creates obligations that many current drug and alcohol policies do not yet address.

The core challenge is the gap between detection and impairment. THC, the psychoactive compound in cannabis, can remain detectable in oral fluid and urine for hours to days after the impairment window has passed. A positive test result, in isolation, does not establish that a worker was impaired at the time of testing. At the same time, employers carry a non-delegable duty of care under WHS legislation to manage fitness for work and "the worker has a prescription" is not a sufficient answer to that obligation.

The regulatory framework across Australian jurisdictions reflects this tension without fully resolving it. Employers operating in safety-critical industries need to understand how their obligations vary by state and territory:

The practical response for most employers is a combination of clear policy wording that addresses prescribed cannabis alongside other prescribed medications, documented reasonable-suspicion observation protocols, and a consistent approach to fitness-for-work assessment that does not rely solely on a positive test result. Andatech's article on what Australian employers are required to do when a worker holds a medicinal cannabis prescription covers the policy-building requirements in detail and provides a useful starting point for HR and WHS teams reviewing their current documentation.

Integrated Testing Programs Reduce Risk and Deliver Measurable Returns

A drug and alcohol program built on occasional testing and a policy document that has not been reviewed since the last enterprise agreement is not a program, it’s a liability. Safety leaders who attended WHS Show Melbourne 2026 arrived from organisations at different points on this spectrum, but the business case for a structured, integrated approach applies across all of them.

The scale of the operating environment makes this case plainly. Australian consumption of methylamphetamine, cocaine, MDMA and heroin in the 12 months to August 2025 reached an estimated 22.2 tonnes, a 34% increase on the prior year, according to national wastewater analysis data. Cannabis remains the most frequently detected substance in workplace drug testing programs. The financial exposure attached to impairment-related incidents includes workers compensation claims, incident investigation costs, productivity losses, potential WHS prosecution costs and reputational damage that does not appear on a balance sheet until well after the event.

An integrated program addresses each layer of this exposure through four interconnected components:

1. Policy: A current, legally reviewed drug and alcohol policy that addresses prescribed medications, medicinal cannabis, reasonable suspicion, testing procedures and consequences
2. Testing: A method mix appropriate to the workforce and industry, combining oral fluid screening for real-time safety decisions with urine testing where longer-window monitoring is required, and breath alcohol testing using AS 3547:2019-compliant devices such as the Prodigy S portable breathalyser and Soberlive FRX for fixed-point entry screening
3. Result management: Centralised, audit-ready documentation that creates a defensible compliance record across all sites and testing events
4. Support: Structured pathways for workers who return a positive result, covering Employee Assistance Programme referral, return-to-work protocols and documented follow-up

The return on this investment is best expressed in terms of risk reduction rather than direct financial modelling, which requires organisation-specific data. What the evidence supports is that a program with all four components in place creates significantly more defensible outcomes than a program that addresses only one or two.

Drug and Alcohol Policy Works Best When Support Is Built In

A workplace drug and alcohol policy that treats a positive test result as a straight path to disciplinary action is increasingly difficult to defend legally, operationally and culturally. The shift in Australian workplaces toward a support-integrated model reflects both Fair Work jurisprudence and a growing body of WHS guidance that frames early intervention as a duty-of-care obligation, not an optional extension of an employer's wellbeing strategy.

The practical effect of this shift is that a positive test result should trigger a structured response process, not an immediate dismissal decision. That process needs to be documented in the policy, consistently applied across the workforce and understood by managers before a testing event occurs. A compliant and defensible support framework includes the following components:

1. A written policy that specifies what happens following a positive result, including who is notified, what work restrictions apply and what support is offered
2. Access to an Employee Assistance Programme with referral pathways to occupational health or addiction support services
3. A documented return-to-work protocol for workers returning after a positive result, including a defined testing schedule and any conditions on duties
4. Manager training in reasonable-suspicion observation, so that fitness-for-work concerns are documented accurately before a test is initiated
5. A consistent enforcement record across the workforce — inconsistency in applying the policy is one of the most common grounds on which positive-result decisions are successfully challenged in Fair Work proceedings

The testing infrastructure and the support framework are not separate programs. A well-managed result management system provides the foundation on which a support-integrated response is built. Andatech's resources on what a defensible drug and alcohol policy includes offer a practical framework for organisations at any stage of this process.

Adelaide Institute of Health & Safety Show Adelaide 2026

These five shifts represent the current leading edge of drug and alcohol compliance practice in Australia. They are not independent developments. They reinforce each other, and organisations that address them as a connected program rather than isolated initiatives build compliance structures that are both more defensible and more durable.

AIHS Show Adelaide 2026 is the right setting to work through the practical implications. Safety leaders will find peers dealing with the same challenges, regulators discussing the direction of WHS obligations and suppliers who can demonstrate how their solutions perform in real operating conditions. For those with gaps in any of these five areas, the show is two days of concentrated, directly applicable intelligence.

Meet the Andatech team at AIHS Show Adelaide 2026

Andatech will be exhibiting at the Adelaide Convention Centre on 16 and 17 June 2026. Visit the stand to see live demonstrations of the DrugSense OraScan 3000 Analyser, Prodigy S portable breathalyser and Andalink platform, and to speak with the team about building a compliant, defensible drug and alcohol program for your workplace.

Register for 2026 Adelaide Institute of Health & Safety Show